Opening a US Telehealth Peptide Business
Compliant launch blueprint across regulatory framework, corporate structure, payment processing, marketing, insurance, financial model, exit risk, and a 22-peptide product menu stratification
Bottom line up front
The US telehealth compounded-peptide market is in active, large-scale operation despite intensifying federal pressure: Eden, Mochi, Henry Meds, Noom Med, Willow, MEDVi, Ro, Good Life Meds, Tactus Health, and others all remain live as of May 2026 — though Hims & Hers (NYSE: HIMS) was DOJ-referred Feb 6 2026 and exited compounded GLP-1s in March 2026 (Q1 2026 net loss $92.1M, gross margin compressed 73%→65%) and 70+ telehealth operators received FDA warning letters in the September 2025 and February 2026 waves.
AI Verdict
Go with caveats
3 key risks identified
Confidence
68%
Calibrated against 330 citations.
Sections
10
Read time
73 min
Sources
330
Why this could work
- 1
STRICT-READING: Federal enforcement against the broad-menu compounded-peptide telehealth model is the most aggressive in the category's history — 50+ FDA warning letters Sept 2025, 30 more Feb 2026, the DOJ Tailor Made guilty plea covering 8 of the user's 22 peptides (BPC-157, CJC-1295, DSIP, Epitalon, Ipamorelin, Melanotan 2, Selank, Semax) — plus 3 combination products (GLOW, K-L-O-W, BPC/TB-4 combo) containing TMC-named peptides, the FDA March 31 2026 Gram Peptides letter rejecting RUO disclaimers as 'ruse', the Mastercard June 2025 BRAM termination of hybrid Rx+RUO merchants, and the Eli Lilly v. Mochi/Fella/Willow/Henry suits — all stack against an unfiltered 22-peptide launch.
- 2
OPERATIONAL REALITY: Despite that enforcement, multiple specialty operators are running compliant peptide-telehealth businesses today — Eden Health ($229-329/mo GLP-1 + NAD+ + sermorelin + GHK-Cu Foam, no FDA letter), Mochi ($278/mo all-in compounded tirzepatide with B12 combination carve-out, Eli Lilly defendant but live), Good Life Meds (NAD+ + sermorelin + Microdose GLP-1, no enforcement), and Tactus Health (sermorelin + PT-141 only as the compliance flagship); the friendly-PC + MSO + LegitScript + high-risk-processor pattern is reproducible.
- 3
STRATIFIED MENU IS THE WIN CONDITION: A Tier-1 launch (NAD+ injectable + topical GHK-Cu + branded Egrifta/Vyleesi/Scenesse where indication overlaps) plus a calendared Tier-2 add-on schedule anchored to the July 23-24 2026 PCAC outcome and downstream FDA rulemaking, with CJC-1295/Ipamorelin held back, Melanotan 2/SS-31/Retatrutide avoided, and the hybrid Rx+RUO model rejected, is the operationally defensible path; even a Tier 1+2 menu would still be selling MORE peptides than Eden's 3-SKU live menu — that's a positioning consideration.
What could kill it
- !
FDA enforcement cascade if launching with a broad.
menu before the July 23-24 2026 PCAC outcome and downstream rulemaking — combined with state board action against the prescribing physician and pharmacy partner (the §1 four-medical-group concentration risk: Beluga / OpenLoop / MD Integrations / Telegra sit behind 30%+ of FDA-warned telehealth operators).
- !
Payment processor termination cascade — Stripe/PayPal/Square/Shopify all prohibit.
the category, high-risk processors hold 5-10% rolling reserves for 90-180 days, Visa VAMP tightening to 1.5% chargeback ratio April 2026 plus Mastercard ECM at 100+ chargebacks + 1.5% ratio = single processor termination freezes 100% of receivables; without dual-MID failover the venture cannot collect new revenue for 30-180 days.
- !
Founder personal-liability tail surviving corporate dissolution — claims-made.
med-mal tail at 150-300% of last annual premium (one-time, due at termination), Park Doctrine strict criminal liability for FDCA misdemeanors without scienter, IRC §6672 trust-fund-recovery for unpaid payroll/sales tax (no SOL), and products-liability latent-injury exposure for 2-10 years post-wind-down.
Before you spend a dollar — do these 10 things
01
OperationalBuild to the compliant pattern documented in Hims's 10-K (friendly-PC + MSO.
+ 503A pharmacy partner + LegitScript-certified high-risk payment processor) but start narrower than any current operator: NAD+ injectable + topical GHK-Cu + branded Egrifta/Vyleesi/Scenesse where the FDA-approved indication overlaps your patient population.
02
RegulatoryLaunch with sermorelin (clean 503A component-of-FDA-approved-drug pathway), tesamorelin via branded Egrifta only.
(not compounded), and any GLP-1 prescribing routed through the documented patient-specific 503A carve-outs (allergy / dose-route / combination) that Eden, Mochi, Henry, and Noom are using live as of May 2026.
03
StrategicForm the MSO as a Delaware LLC (institutional-investor friendly + flat $300.
annual franchise tax) and a separate friendly PC in each CPOM state of operation, with a master MSA using a fixed monthly fee at FMV (documented by independent valuation, not percentage-of-revenue) and narrow Continuity/TRA terms triggered only on license loss, federal-program exclusion, felony indictment, disability/death, or material MSA breach.
04
StrategicSkip mainstream processors entirely from day 1 — attempting Stripe means deferred.
termination plus 90-180 day reserve freeze on receivables.
05
RegulatoryForm the MSO as a Delaware LLC ($110 + $300/yr); form the.
PC in each ship-to CPOM state's required entity type (CA: PC under Moscone-Knox; NJ: PC only; GA: PC + Medical Board pre-approval; TX/FL/NY/IL/MI/OH/VA/NC: PLLC).
06
StrategicBind the program in this order before first patient consult: (1) physician.
med-mal claims-made with TDC or MedPro, explicit endorsement disclosing every peptide protocol AND tail provision negotiated upfront in physician services agreement; (2) MSO E&O + Tech E&O + Cyber bundled (Admiral or Beazley digital health) at $2-5M cyber sub-limit; (3) products liability allocated via written named-additional-insured cert from compounding pharmacy partner with annual delivery confirmation, plus an independent MSO/PC products policy (Hiscox Healthcare or Embroker) as DIC layer if pharmacy carrier non-renews; (4) D&O bound with bodily-injury carve-back for securities claims and explicit acknowledgment that FDA/state-board regulatory action defense is uninsured (budget separate counsel retainer for that); (5) BAAs signed with every PHI-touching vendor (EHR, telehealth video, support tooling, payment processor if PHI flows).
07
StrategicHold LegitScript Healthcare Merchant Certification before ANY paid placement on Meta, Google,.
or Microsoft (also gates payment-processor underwriting per §4).
08
FinancialRun the CostEstimator widget below with conservative inputs ($199 subscription, $60 COGS.
+ $65 cold-chain + $25 physician + $8 support per Rx, 4.5% processing + 5% reserve carry, 10% monthly churn, $250 CAC) — expect LTV:CAC ratio in 2-3:1 range, which is self-fund-only territory not fundable territory.
09
StrategicArchitect for involuntary exit from day 1: (1) claims-made med-mal with tail.
provision negotiated upfront in physician services agreement (who pays the 150-300% premium, what triggers it), (2) dual-MID payment architecture with both processors pre-underwritten and warm-routed, (3) backup 503A pharmacy qualified before launch, (4) regulatory counsel on standing retainer (Hyman Phelps & McNamara, Frier Levitt, King & Spalding Life Sciences, Sidley Austin Food + Drug), (5) cash plan to operate 6 months without revenue collection (rolling reserve trap + dual-MID failover gap), (6) Compliance Binder updated quarterly so a 363 distressed sale is executable in 60 days if needed.
10
StrategicLAUNCH WEEK 1: NAD+ injectable (500mg + 1000mg dose tiers, Eden $186-246/mo.
benchmark), GHK-Cu topical Foam (Eden precedent, men + women, hair growth indication), and if your prescribing physician is comfortable, sermorelin under the §2 Geref-component pathway (Tactus precedent).
The deep dive
10 sections · 73 min · 330 cited facts
Section 01
Live Operator Landscape
The live operator landscape is the empirical proof that this venture has a path — 12+ named companies are operating compliantly under documented patient-specific 503A carve-outs as of May 2026 — but it is also proof that the user's 22-peptide menu is wildly out of step with what actually scales in this market.
Section 02
Regulatory Framework
The federal regulatory layer in May 2026 has narrowed to a knife-edge: sermorelin via Geref-component pathway and four-per-month GLP-1 patient-specific carve-outs are the only clean compounding paths today, with everything else (BPC-157, TB-500, CJC-1295, ipamorelin, KPV, MOTS-C, DSIP, Epitalon, Semax) waiting on a July 23-24 2026 PCAC outcome that is itself only an advisory step before FDA rulemaking.
Section 03
Corporate Structure & Physician Relationship
The friendly PC + MSO structure used by Hims, Ro, Mochi, and Henry Meds is the dominant validated solution, but recent rulings (Art Center Holdings v.
Section 04
Payment Processing & Banking
Payment processing is the single hardest operational pillar — Stripe/Square/PayPal/Shopify all prohibit the category through multiple AUP clauses, and even specialized high-risk processors enforce 5-10% rolling reserves with 90-180 day holds plus card-brand monitoring (VAMP 1.5% threshold tightening April 2026) that can trigger account termination on chargeback drift alone.
Section 05
Business Entity & Licensing
Delaware MSO + state-specific PC (PLLC where allowed, traditional PC in CA/NJ/GA) is the validated venture-scale architecture; FinCEN BOI is currently non-issue for US-formed entities under the March 2025 IFR, but the MSA fee carries state-specific tax exposure in NM/HI/WA/SD that materially affects MSA pricing.
Section 06
Insurance & Liability
Insurance must explicitly contemplate that standard med-mal policies categorically exclude unapproved medications absent endorsement, that the OpenLoop Jan 2026 BAA-chain breach proves BAAs are necessary but not sufficient, and that D&O's regulatory-action exclusion means FDA enforcement defense is generally uninsured — the venture's policy stack must be layered and disclosed-not-omitted, not stitched together by an inexperienced broker.
Section 07
Marketing Rules & Restrictions
The compliant marketing playbook is unambiguous: advertise the consultation, condition, and patient experience — never the specific peptide by name or 'sameness' claim — under LegitScript Healthcare Merchant Certification on Meta and Google, with no paid TikTok or X (effectively closed), no patient testimonials in New York under §6530(27), no before/after photos without §651 / Rule 164.3-compliant disclosures, and a per-ad-creative gate that the marketing team runs before publishing.
Section 08
Financial Model & Unit Economics
The HIMS comp ($83 MORPAS, 74% GM, 39% marketing, sub-1-yr CAC payback) reflects scale + brand + a now-defunct compounded GLP-1 economics layer; a single-product peptide startup operating in advertising-restricted channels with no GLP-1 demand anchor cannot rely on those benchmarks — model conservatively at $99-299 ARPU, 50%+ marketing-to-revenue, 10-12% monthly churn (vs HIMS's 70% week-12 retention only achievable with GLP-1 clinical anchor).
Section 09
Exit & Wind-down Risks
Exit is dominated by involuntary triggers — FDA warning letters (15-day clock), state board summary suspensions (30-day Ohio model), processor terminations (180-day reserve freeze + 5-year MATCH listing), pharmacy partner enforcement, products-liability lawsuits, HIPAA breaches > 500 records — and the founder personal-liability tail survives corporate dissolution under three independent doctrines (claims-made med-mal tail at 150-300% of last premium, Park Doctrine strict criminal liability for FDCA misdemeanors, IRC §6672 trust-fund-recovery with no SOL).
Section 10
Product Menu & Molecule Stratification
Of the user's 22-peptide menu, ONLY NAD+ injectable and topical GHK-Cu pass a 2026 clean compliance screen as Tier 1 launch products today; Tier 2 (BPC-157, TB-4, KPV, MOTS-C, Epitalon, DSIP, Semax) requires the July 23-24 2026 PCAC outcome AND downstream FDA rulemaking before adding; Tier 3 (CJC-1295, Ipamorelin) requires extraordinary documented patient-specific clinical justification and is RECOMMENDED SKIP per the Tactus Health compliance posture; Branded Rx (PT-141 via Vyleesi where indication overlaps) is the only PT-141 pathway; FULLY AVOID (Tesamorelin compounded, Melanotan 1, Melanotan 2, SS-31, Retatrutide, BPC/TB-4 combo, GLOW, K-L-O-W combo); RUO-or-skip and recommended SKIP (Selank, ARA-290).
Outstanding issues from AI critic (round 1)
Critic review complete
These were reviewed by the AI critic but did not require changes.
AI critic ran 1 round and found no remaining issues.